Aptinyx Inc. (APTX)

Market Cap	28.44M
Revenue (ttm)	n/a
Net Income (ttm)	-78.34M
Shares Out	67.72M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	651,735
Open	0.420
Previous Close	0.430
Day's Range	0.400 - 0.430
52-Week Range	0.330 - 3.760
Beta	1.28
Analysts	Buy
Price Target	2.55 (+507.1%)
Earnings Date	Nov 7, 2022

About APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical t...

• Industry: Biotechnology
• IPO Date: Jun 21, 2018
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: APTX

Full Company Profile

Financial Performance

In 2021, Aptinyx's revenue was $1,000,000, a decrease of -36.06% compared to the previous year's $1.56 million. Losses were -$74.89 million, 49.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for APTX stock is "Buy." The 12-month stock price forecast is 2.55, which is an increase of 507.14% from the latest price.

Price Target

$2.55

(507.14% upside)

Analyst Consensus: Buy

Stock Forecasts